KEAP1 and bronchopulmonary dysplasia: While several individual antioxidant trials failed to show promising results in BPD patients13, the present study uncovered that targeting Keap1 to broadly activate Nrf2-regulated gene expression may be crucial to mitigate hypoalveolarization associated with prematurity in the clinical setting.